| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Medicine, University of Toronto; the Division of Clinical Epidemiology, Wellesley Hospital Research Institute, Toronto, Ontario, Canada
2 From the Department of Medicine, University of Toronto; the Division of Respirology, West Park Hospital, Toronto, Ontario, Canada
3 From the Department of Medicine, University of Toronto; the Division of Respirology, Wellesley Hospital, Toronto, Ontario, Canada
Objective: To determine when a difference in FEV1 is sufficiently large to be associated with a noticeable difference in dyspnea symptoms for patients with chronic lung disease.
Design: Cross-sectional analysis of 15 groups (n=112 patients, 832 contrasts).
Setting: Respiratory rehabilitation program.
Patients: Patients with COPD (mean FEV1=35% predicted).
Measures: Patients' perspectives assessed through subjective comparison ratings of dyspnea and of overall health. Relation between the FEV1 and patients' perspectives determined the smallest difference in spirometry that was associated with a noticeable difference in patients' symptoms.
Results: The FEV1 was moderately correlated with patients' ratings of dyspnea (r=0.29; 95% confidence interval (CI), 0.22 to 0.35). In contrast, the FEV1 was minimally correlated with patients' ratings of overall health (r=0.10; 95% CI, 0.03 to 0.17). The FEV1 needed to differ by 4% predicted for the average patient to stop rating his or her dyspnea as "about the same" and start rating his or her dyspnea as either "a little bit better" or "a little bit worse" relative to other patients (95% CI, 1.5 to 6.5). This was equivalent to the average patient's FEV1 increasing by 112 mL (starting from 975 mL and ending at 1,087 mL).
Conclusions: Some statistically significant differences in the FEV1 are so small that they may not represent important differences in symptoms for the average patient with severe COPD; an awareness of the smallest difference in FEV1 that is noticeable to patients can help clinicians interpret the effectiveness of symptomatic treatments.
Key Words: COPD • dyspnea • spirometry
Submitted on September 18, 1995
Accepted on December 5, 2007
This article has been cited by other articles:
|
|
 |
|
  G. J. Rodrigo, L. J. Nannini, and R. Rodriguez-Roisin Safety of Long-Acting {beta}-Agonists in Stable COPD: A Systematic Review Chest, May 1, 2008; 133(5): 1079 - 1087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Soriano, D. D. Sin, X. Zhang, P. G. Camp, J. A. Anderson, N. R. Anthonisen, A. S. Buist, P. S. Burge, P. M. Calverley, J. E. Connett, et al. A Pooled Analysis of FEV1 Decline in COPD Patients Randomized to Inhaled Corticosteroids or Placebo Chest, March 1, 2007; 131(3): 682 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R G Barr, J Bourbeau, C A Camargo, and F S F Ram Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis Thorax, October 1, 2006; 61(10): 854 - 862. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Herpel, R. E. Kanner, S. M. Lee, H. E. Fessler, F. C. Sciurba, J. E. Connett, R. A. Wise, and for the Lung Health Study Research Group and the N Variability of Spirometry in Chronic Obstructive Pulmonary Disease: Results from Two Clinical Trials Am. J. Respir. Crit. Care Med., May 15, 2006; 173(10): 1106 - 1113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Miller, R. A. Malthaner, C. H. Goldsmith, R. Goeree, D. Higgins, P. G. Cox, L. Tan, J. D. Road, and Canadian Lung Volume Reduction Surgery Study A Randomized Clinical Trial of Lung Volume Reduction Surgery Versus Best Medical Care for Patients With Advanced Emphysema: A Two-Year Study From Canada Ann. Thorac. Surg., January 1, 2006; 81(1): 314 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Pellegrino, G. Viegi, V. Brusasco, R. O. Crapo, F. Burgos, R. Casaburi, A. Coates, C. P. M. van der Grinten, P. Gustafsson, J. Hankinson, et al. Interpretative strategies for lung function tests Eur. Respir. J., November 1, 2005; 26(5): 948 - 968. [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Donohue and J. A. Ohar Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Dheda, A Crawford, G Hagan, and C M Roberts Implementation of British Thoracic Society guidelines for acute exacerbation of chronic obstructive pulmonary disease: impact on quality of life Postgrad. Med. J., March 1, 2004; 80(941): 169 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Aaron, K. L. Vandemheen, P. Hebert, R. Dales, I. G. Stiell, J. Ahuja, G. Dickinson, R. Brison, B. H. Rowe, J. Dreyer, et al. Outpatient Oral Prednisone after Emergency Treatment of Chronic Obstructive Pulmonary Disease N. Engl. J. Med., June 26, 2003; 348(26): 2618 - 2625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R S Goldstein, T R J Todd, G Guyatt, S Keshavjee, T E Dolmage, S van Rooy, B Krip, F Maltais, P LeBlanc, S Pakhale, et al. Influence of lung volume reduction surgery (LVRS) on health related quality of life in patients with chronic obstructive pulmonary disease Thorax, May 1, 2003; 58(5): 405 - 410. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Szafranski, A. Cukier, A. Ramirez, G. Menga, R. Sansores, S. Nahabedian, S. Peterson, and H. Olsson Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease Eur. Respir. J., January 1, 2003; 21(1): 74 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. Singh, V. A. Palda, M. B. Stanbrook, and K. R. Chapman Corticosteroid Therapy for Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review Arch Intern Med, December 9, 2002; 162(22): 2527 - 2536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hajiro and K. Nishimura Minimal clinically significant difference in health status: the thorny path of health status measures? Eur. Respir. J., March 1, 2002; 19(3): 390 - 391. [Full Text] [PDF]
|
|
|
|
|
|
P.W. Jones Interpreting thresholds for a clinically significant change in health status in asthma and COPD Eur. Respir. J., March 1, 2002; 19(3): 398 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Aaron, K. L. Vandemheen, J. J. Clinch, J. Ahuja, R. J. Brison, G. Dickinson, and P. C. Hebert Measurement of Short-term Changes in Dyspnea and Disease-Specific Quality of Life Following an Acute COPD Exacerbation Chest, March 1, 2002; 121(3): 688 - 696. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. H. Wijnhoven, D. M. W. Kriegsman, A. E. Hesselink, B. W. J. H. Penninx, and M. de Haan Determinants of Different Dimensions of Disease Severity in Asthma and COPD : Pulmonary Function and Health-Related Quality of Life Chest, April 1, 2001; 119(4): 1034 - 1042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Redelmeier, M. J. Schull, J. E. Hux, J. V. Tu, and L. E. Ferris Problems for clinical judgement: 1. Eliciting an insightful history of present illness Can. Med. Assoc. J., March 1, 2001; 164(5): 647 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. D. Yusen What Outcomes Should Be Measured in Patients With COPD? Chest, February 1, 2001; 119(2): 327 - 328. [Full Text] [PDF]
|
|
|
|
|
|
I. M. Ferreira, D. Brooks, Y. Lacasse, and R. S. Goldstein Nutritional Support for Individuals With COPD: A Meta-analysis Chest, March 1, 2000; 117(3): 672 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bell, D. Urbach, M. D. Eisner, and P. D. Blanc Bartenders' Pulmonary Function After Establishment of a Smoke-Free Workplace JAMA, August 18, 1999; 282(7): 629 - 629. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
